News

Generics perceptions in patients, pharmacists and doctors

Published on 2017/03/03

A significant proportion of the general public, pharmacists and doctors have negative perceptions about generics, according to a study carried out by researchers from New Zealand and the US [1]. ...

10 views

Read more →

Switching between originator and follow-on iron-sucrose

Published on 2017/03/01

Researchers from France describe and compare the haematological parameters and anaemia medications used in chronic kidney disease (CKD) patients undergoing haemodialysis, before and after switchin...

7 views

Read more →

Substitution of generic antiepileptic drugs

Published on 2016/12/12

Despite the availability of generic antiepileptic drugs (AEDs), patients and neurologists still hesitate to make a switch due to several reasons. The objectives of this review were to eva...

14 views

Read more →

Biosimilars: management of clinical issues

Published on 2016/12/09

How to manage clinical issues encountered with biosimilars was a topic discussed in a review of biosimilars in rheumatology by author José M Serra López-Matencio and colleagues from the Universi...

6 views

Read more →

Payers in US view biosimilars as a lower-cost branded option

Published on 2016/12/07

Payers in the US do not expect the biosimilars market to be like the generics market and they also do not expect the US biosimilars market to be like that in Europe, according to a report publishe...

7 views

Read more →

A multidisciplinary perspective on biosimilars

Published on 2016/12/05

A biosimilar is an officially regulated and approved copy of an originator biological therapy. Authors Khraishi et al. aimed to provide a comprehensive review of the biosimilar development process...

4 views

Read more →

FDA issues draft guidance on biosimilars labelling

Published on 2016/12/02

The US Food and Drug Administration (FDA) announced on 31 March 2016 that it had issued draft guidance for industry on labelling for biosimilars. The guidance is open for comment for a period of t...

12 views

Read more →

European regulatory pathways for biosimilars

Published on 2016/11/30

The European regulatory pathways for biosimilars were discussed in a review of biosimilars in rheumatology by author José M Serra López-Matencio and colleagues from the Universidad Autónoma, Ma...

11 views

Read more →

Impact of antidepressant generics in Europe

Published on 2016/11/28

Use of generic antidepressants may improve adherence and reduce the cost of pharmacotherapy for depression in European countries, according to a report by the Germany-based Institute for Healthcar...

3 views

Read more →

Biologicals: characteristics that make them unique and special

Published on 2016/11/25

The unique characteristics of biologicals were discussed in a review of biosimilars in rheumatology by author José M Serra López-Matencio and colleagues from the Universidad Autónoma, Madrid, S...

6 views

Read more →

Impact of South Korea’s new drug–pricing policy on market competition

Published on 2016/11/23

In April 2012, the Korean Government implemented a new policy to try and make its multiple sourced (off-patent) market more competitive. Their objective was to lower the price of generics through ...

13 views

Read more →

How the biosimilars market is changing

Published on 2016/11/21

Access to high quality medicine at affordable prices without jeopardizing patients’ health is one of the key challenges in developed countries where rising life expectancy and growing average ag...

8 views

Read more →